NCT02849990View on ClinicalTrials.gov

A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

March 9, 2017

Primary Completion Date

December 10, 2018

Study Completion Date

December 10, 2020

Conditions
Stage III Prostate Adenocarcinoma AJCC v7Stage III Prostate Cancer AJCC v7Stage IV Prostate Adenocarcinoma AJCC v7Stage IV Prostate Cancer AJCC v7
Interventions
DRUG

Abiraterone Acetate

Given PO

DRUG

Apalutamide

Given PO

DRUG

Degarelix

Given SC

DRUG

Indomethacin

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative study

DRUG

Prednisone

Given PO

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

Janssen Scientific Affairs, LLC

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

University of Washington

OTHER

NCT02849990 - A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy | Biotech Hunter | Biotech Hunter